ROS Cancer Research Results

ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination

Item ROS NRF2 Condition Mechanism Class Remarks
ROS">Piperlongumine +++ [D][T] ROS-dominant
ROS">Shikonin +++↓/±[D][T]ROS-dominant
ROS">Vitamin K3 (menadione) +++[D]ROS-dominant
ROS">Copper (ionic / nano) +++[Fe][F]ROS-dominant
ROS">Sodium Selenite +++[D]ROS-dominant
ROS">Juglone +++[D]ROS-dominant
ROS">Auranofin +++[D]ROS-dominant
ROS">Photodynamic Therapy (PDT) +++0[L][O₂]ROS-dominant
ROS">Radiotherapy / Radiation +++0[O₂]ROS-dominant
ROS">Doxorubicin +++[D]ROS-dominant
ROS">Cisplatin ++[D][T]ROS-dominant
ROS">Salinomycin ++[D][T]ROS-dominant
ROS">Artemisinin / DHA ++[Fe][T]ROS-dominant
ROS">Sulfasalazine ++[C][T]ROS-dominant
ROS">FMD / fasting ++[M][C][O₂]ROS-dominant
ROS">Vitamin C (pharmacologic) ++[Fe][D]ROS-dominant
ROS">Silver nanoparticles ++±[F][D]ROS-dominant
ROS">Gambogic acid ++[D][T]ROS-dominant
ROS">Parthenolide ++[D][T]ROS-dominant
ROS">Plumbagin ++[D]ROS-dominant
ROS">Allicin ++[D]ROS-dominant
ROS">Ashwagandha (Withaferin A) ++[D][T]ROS-dominant
ROS">Berberine ++[D][M]ROS-dominant
ROS">PEITC ++[D][C]ROS-dominant
ROS">Methionine restriction +[M][C][T]ROS-secondary
ROS">DCA +±[M][T]ROS-secondary
ROS">Capsaicin +±[D][T]ROS-secondary
ROS">Galloflavin +0[D]ROS-secondary
ROS">Piperine +±[D][F]ROS-secondary
ROS">Propyl gallate +[D]ROS-secondary
ROS">Scoulerine +?[D][T]ROS-secondary
ROS">Thymoquinone ±±[D][T]Dual redox
ROS">Emodin ±±[D][T]Dual redox
ROS">Alpha-lipoic acid (ALA) ±[D][M]NRF2-dominant
ROS">Curcumin ±↑/↓[D][F]NRF2-dominant
ROS">EGCG ±↑/↓[D][O₂]NRF2-dominant
ROS">Quercetin ±↑/↓[D][Fe]NRF2-dominant
ROS">Resveratrol ±[D][M]NRF2-dominant
ROS">Sulforaphane ±↑↑[D]NRF2-dominant
ROS">Lycopene 0Antioxidant
ROS">Rosmarinic acid 0Antioxidant
ROS">Citrate 00Neutral


BC, Breast Cancer: Click to Expand ⟱
Breast Cancer

Scientific Papers found: Click to Expand⟱
5461- AF,    Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
Paraptosis↑, ER Stress↑, TrxR↓, selectivity↑, toxicity↝, ROS↑, mt-TrxR1↓, mt-TrxR2↓,
4400- AgNPs,  Rad,    Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
- in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, BC, MDA-MB-231
ROS↑, DNAdam↑, selectivity↑, TumCG↓, RadioS↑, Dose↝, selectivity↑, other↝, eff↓, eff↑, γH2AX↑, Dose↓, eff↑,
4417- AgNPs,    Caffeine-boosted silver nanoparticles target breast cancer cells by triggering oxidative stress, inflammation, and apoptotic pathways
- in-vitro, BC, MDA-MB-231
ROS↑, MDA↑, COX2↑, IL1β↑, TNF-α↑, GSH↓, Cyt‑c↑, Casp3↑, BAX↑, Bcl-2↓, LDH↓, cycD1/CCND1↓, CDK2↓, TumCCA↑, mt-Apoptosis↑,
4415- AgNPs,  SDT,  CUR,    Examining the Impact of Sonodynamic Therapy With Ultrasound Wave in the Presence of Curcumin-Coated Silver Nanoparticles on the Apoptosis of MCF7 Breast Cancer Cells
- in-vitro, BC, MCF-7
tumCV↓, BAX↑, Casp3↑, Bcl-2↓, eff↑, ROS↑, sonoS↑, eff↑, MMP↓, Cyt‑c↑,
4413- AgNPs,  Anzaroot,    Green synthesis of silver nanoparticles from plant Astragalus fasciculifolius Bioss and evaluating cytotoxic effects on MCF7 human breast cancer cells
- in-vitro, BC, MCF-7
chemoP↑, TumCG↓, eff↑, CellMemb↑, selectivity↑, ROS↑, P53↑,
4431- AgNPs,  doxoR,    Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1 - in-vitro, Nor, 3T3
AntiCan↑, ROS↑, TumVol↓, EPR↑, selectivity↑, ChemoSen↑,
4364- AgNPs,    Selective cytotoxicity of green synthesized silver nanoparticles against the MCF-7 tumor cell line and their enhanced antioxidant and antimicrobial properties
- in-vitro, BC, MCF-7
TumCD↑, selectivity↑, *antiOx↑, *Inflam↓, AntiTum↑, ROS↑,
4563- AgNPs,  Rad,    Silver nanoparticles enhance neutron radiation sensitivity in cancer cells: An in vitro study
- in-vitro, BC, MCF-7 - in-vitro, Ovarian, SKOV3 - in-vitro, GBM, U87MG - in-vitro, Melanoma, A431
RadioS↑, ROS↑, TumCCA↑, Apoptosis↑, ER Stress↑,
4559- AgNPs,    Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation
- in-vitro, BC, SkBr3 - in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, Colon, Caco-2
MMP2↓, MMP9↓, ROS↑, TumAuto↑, Apoptosis↑, ER Stress↑,
316- AgNPs,    Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells
- in-vitro, BC, MCF-7
GRP78/BiP↑, ER Stress↑, ROS↑, mtDam↑,
374- AgNPs,    Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
ER Stress↑, DNAdam↑, ROS↑, Apoptosis↑, GSH/GSSG↓, NADPH/NADP+↓, TumCG↓, UPR↑,
348- AgNPs,    Induction of p53 mediated mitochondrial apoptosis and cell cycle arrest in human breast cancer cells by plant mediated synthesis of silver nanoparticles from Bergenia ligulata (Whole plant)
- in-vitro, BC, MCF-7
Apoptosis↑, ROS↑, MMP↓, P53↑, BAX↑, cl‑Casp3↑,
349- AgNPs,    Insight into the molecular mechanism, cytotoxic, and anticancer activities of phyto-reduced silver nanoparticles in MCF-7 breast cancer cell lines
- in-vitro, BC, MCF-7
Apoptosis↑, ROS↑, CellMemb↑,
350- AgNPs,    Cytotoxic and Apoptotic Effects of Green Synthesized Silver Nanoparticles via Reactive Oxygen Species-Mediated Mitochondrial Pathway in Human Breast Cancer Cells
- in-vitro, BC, MCF-7
ROS↑, MMP↓, P53↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓,
356- AgNPs,  MF,    Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study
- in-vitro, BC, MCF-7 - in-vitro, Bladder, HTB-22
Apoptosis↑, P53↑, iNOS↑, NF-kB↑, Bcl-2↓, ROS↑, SOD↑, TumCCA↑, eff↑, Catalase↑, other↑,
353- AgNPs,    The mechanism of cell death induced by silver nanoparticles is distinct from silver cations
- in-vitro, BC, SUM159
lipid-P↑, H2O2↑, ROS↑, Apoptosis↑,
377- AgNPs,    Anticancer Action of Silver Nanoparticles in SKBR3 Breast Cancer Cells through Promotion of Oxidative Stress and Apoptosis
- in-vitro, BC, SkBr3
ROS↑, Apoptosis↑, Bax:Bcl2↑, VEGF↑, Akt↓, PI3K↓, TAC↓, TOS↑, OSI↑, MDA↑, Casp3↑, Casp7↑,
402- AgNPs,  MF,    Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study
- in-vitro, BC, MCF-7
P53↑, iNOS↑, NF-kB↑, Bcl-2↓, miR-125b↓, ROS↑, SOD↑,
388- AgNPs,    Apoptotic efficacy of multifaceted biosynthesized silver nanoparticles on human adenocarcinoma cells
- in-vitro, BC, MCF-7
ROS↑, Casp3↑, BAX↑, P53↑, Casp↑, Cyt‑c↑, MMP↓, DNAdam↑, Bcl-2↓, BAX↑,
390- AgNPs,    Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line
- in-vitro, BC, MDA-MB-231 - in-vivo, BC, NA
ROS↑, TumVol↓,
2000- AL,    Exploring the ROS-mediated anti-cancer potential in human triple-negative breast cancer by garlic bulb extract: A source of therapeutically active compounds
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, NA
selectivity↑, TumCG?, *toxicity∅, ROS↑, MMP↓, TumCCA↑, P53↑, Bcl-2↓, p‑Akt↓, p‑p38↓, *ROS∅,
5167- AL,    The Effects of Allicin, a Reactive Sulfur Species from Garlic, on a Selection of Mammalian Cell Lines
- in-vitro, Nor, 3T3 - in-vitro, BC, MCF-7 - in-vitro, Lung, A549 - in-vitro, CRC, HT-29
Thiols↓, tumCV↓, TumCP↓, GSH↓, GSSG↑, ROS↑,
3434- ALA,    Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
tumCV↓, PI3K↓, p‑Akt↓, p‑P70S6K↓, mTOR↓, ATP↓, GlucoseCon↓, ROS↑, PKM2↓, LDHA↓, Glycolysis↓, ChemoSen↑,
3436- ALA,    Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights Author links open overlay panel
- in-vitro, BC, MCF-7
ChemoSen↑, PI3K↓, Akt↓, ATP↓, GlucoseCon↓, ROS↑, PKM2↓, Glycolysis↓, CSCs↓, IGF-1R↓, Furin↓, RadioS↑,
3454- ALA,    Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
TumCG↑, Glycolysis↓, ROS↑, CSCs↓, selectivity↑, LC3B-II↑, MMP↓, mitResp↓, ATP↓, OCR↓, NAD↓, p‑AMPK↑, GlucoseCon↓, lactateProd↓, HK2↓, PFK↓, LDHA↓, eff↓, mTOR↓, ECAR↓, ALDH↓, CD44↓, CD24↓,
279- ALA,    Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Furin↓, IGF-1R↓, ROS↑, CREB↓, Furin↓, IGF-1R↓,
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
1348- And,    Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
- in-vitro, BC, MCF-7 - in-vitro, BC, T47D - in-vivo, NA, NA
ERα/ESR1↓, TumCG↓, ROS↑, FOXM1↓, eff↑,
1999- Api,  doxoR,    Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation
- in-vitro, Nor, NRK52E - in-vitro, Nor, MPC5 - in-vitro, BC, 4T1 - in-vivo, NA, NA
neuroP↑, ChemoSen∅, RenoP↑, selectivity↑, chemoP↑, ROS↑, *ROS∅, *antiOx↑, *toxicity↓,
2593- Api,    Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo
- in-vivo, BC, 4T1
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↑, ROS↑, p‑PI3K↓, PI3K↓, Akt↓, NRF2↓, AntiTum↑, OS↑,
5376- ART/DHA,    Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, SW48 - in-vitro, BC, MDA-MB-453
Ferroptosis↑, Ferritin↓, Iron↑, eff↑, TumAuto↑, LC3II↑, ROS↑,
5132- ART/DHA,    Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7
Iron↓, TfR1/CD71↓, ROS↑,
1142- Ash,    Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer
- Review, BC, MCF-7 - NA, BC, MDA-MB-231 - NA, Nor, HMEC
Apoptosis↑, ROS↑, DNAdam↑, OXPHOS↓, *ROS∅, Bcl-2↓, XIAP↓, survivin↓, DR5↑, IKKα↓, NF-kB↓, selectivity↑, *ROS∅, eff↓, Paraptosis↑,
1368- Ash,  Cisplatin,    Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’
- in-vitro, Colon, HT-29 - in-vitro, BC, MDA-MB-231
tumCV↓, *toxicity↓, ROS↑, mitResp↓, ChemoSen↑,
1366- Ash,    Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling
- in-vitro, BC, MCF-7
ROS↑, P53↑,
1355- Ash,    Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, HMEC
eff↑, mt-ROS↑, mitResp↓, OXPHOS↓, compIII↑, BAX↑, Bak↑, other↓, ATP∅, *ROS∅,
1359- Ash,    Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
MMP↓, Alix/AIP‑1↓, ROS↑, Paraptosis↑, ER Stress↝,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP↑, p‑eIF2α↑, ICD↑, eff↑,
1367- Ash,    An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
Apoptosis↑, ROS↑, Bax:Bcl2↑, MMP↓, Casp3↑, TumCCA↑,
5385- AsP,  GoldNP,  GEM,    Development of ascorbyl palmitate based hydrophobic gold nanoparticles as a nanocarrier system for gemcitabine delivery
- in-vitro, BC, NA
ROS↑, Fenton↑, BioAv↑, EPR↑,
4978- ATV,  Rad,    Atorvastatin Sensitizes Breast and Lung Cancer Cells to Ionizing Radiation
- in-vitro, BC, A549
Apoptosis↑, RadioS↑, TumCP↓, ROS↑,
1053- Ba,  docx,    Baicalin, a Potent Inhibitor of NF-κB Signaling Pathway, Enhances Chemosensitivity of Breast Cancer Cells to Docetaxel and Inhibits Tumor Growth and Metastasis Both In Vitro and In Vivo
- in-vivo, BC, 4T1
TumCP↓, Apoptosis↑, ROS↑, Bax:Bcl2↑, NF-kB↓, ChemoSen↑, survivin↓,
1385- BBR,  5-FU,    Low-Dose Berberine Attenuates the Anti-Breast Cancer Activity of Chemotherapeutic Agents via Induction of Autophagy and Antioxidation
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
eff↓, ROS↑, TumCP↑, NRF2↑, ChemoSen↓,
1389- BBR,  Lap,    Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS
- in-vitro, BC, BT474 - in-vitro, BC, AU-565
ChemoSen↑, Apoptosis↑, ROS↑, NRF2↓,
1386- BBR,    Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
tumCV↓, ROS↑, JNK↑, MMP↓, Bcl-2↓, BAX↑, Cyt‑c↑, AIF↝,
1473- BCA,  SFN,    An Insight on Synergistic Anti-cancer Efficacy of Biochanin A and Sulforaphane Combination Against Breast Cancer
- in-vitro, BC, MCF-7
eff↑, ROS↑, other↑, ERK↓, Apoptosis↑,
5639- BCA,    Biochanin A Induces Apoptosis in MCF-7 Breast Cancer Cells through Mitochondrial Pathway and Pi3K/AKT Inhibition
- in-vitro, BC, NA
TumCP↓, ROS↑, Apoptosis↑, Bcl-2↓, p‑PI3K↓, p‑Akt↓, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑, CycD3↓, CycB/CCNB1↓, CDK1↓, CDK2↓, CDK4↓, P21↑, p27↑, P53↑, tumCV↓, PI3K↓, Akt↓,
5591- BetA,    Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment
- Review, BC, NA
BioAv↓, BioAv↑, selectivity↑, eff↑, angioG↓, *antiOx↑, *Inflam↓, MMP↓, Bcl-2↓, BAX↑, Casp9↑, Casp3↑, GRP78/BiP?, ER Stress↑, PERK↑, CHOP↑, ChemoSen↑, SESN2↑, ROS↑, MOMP↓, MAPK↑, Cyt‑c↑, AIF↑, STAT3↓, FAK↓, TIMP2↑, TumCMig↓, TumCI↓, Sp1/3/4↓, TumCCA↑, DNAdam↑,
2723- BetA,    Betulinic acid and oleanolic acid modulate CD81 expression and induce apoptosis in triple-negative breast cancer cells through ROS generation
- in-vitro, BC, MDA-MB-231
Apoptosis↑, tumCV↓, ROS↑,
2727- BetA,    Betulinic acid in the treatment of breast cancer: Application and mechanism progress
- Review, BC, NA
mt-ROS↑, Sp1/3/4↓, TumMeta↓, GlucoseCon↓, NF-kB↓, ChemoSen↑, chemoP↑, m-Apoptosis↑, TOP1↓,

Showing Research Papers: 1 to 50 of 151
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 151

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

Catalase↑, 1,   Fenton↑, 1,   Ferroptosis↑, 1,   GSH↓, 2,   GSH/GSSG↓, 1,   GSSG↑, 1,   H2O2↑, 1,   ICD↑, 1,   Iron↓, 1,   Iron↑, 1,   lipid-P↑, 1,   MDA↑, 2,   NADPH/NADP+↓, 1,   NRF2↓, 2,   NRF2↑, 1,   OSI↑, 1,   OXPHOS↓, 2,   ROS↑, 48,   mt-ROS↑, 2,   SOD↑, 2,   TAC↓, 1,   Thiols↓, 1,   TOS↑, 1,   TrxR↓, 1,   mt-TrxR1↓, 1,   mt-TrxR2↓, 1,  

Metal & Cofactor Biology

Ferritin↓, 1,   TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics

AIF↑, 1,   AIF↝, 1,   ATP↓, 3,   ATP∅, 1,   compIII↑, 1,   mitResp↓, 3,   MMP↓, 10,   MMP↑, 1,   mtDam↑, 1,   OCR↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis

AMPK↑, 2,   p‑AMPK↑, 1,   CREB↓, 1,   ECAR↓, 1,   FDG↓, 1,   GlucoseCon↓, 4,   Glycolysis↓, 3,   HK2↓, 1,   lactateProd↓, 1,   LDH↓, 1,   LDHA↓, 2,   NAD↓, 1,   PDH↑, 1,   PFK↓, 1,   PKM2↓, 2,  

Cell Death

Akt↓, 4,   p‑Akt↓, 3,   Apoptosis↑, 19,   m-Apoptosis↑, 1,   mt-Apoptosis↑, 1,   BAD↑, 1,   Bak↑, 2,   BAX↑, 11,   Bax:Bcl2↑, 3,   Bcl-2↓, 12,   Casp↑, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp9↑, 3,   Cyt‑c↑, 6,   DR5↑, 1,   Ferroptosis↑, 1,   iNOS↑, 2,   JNK↑, 1,   MAPK↑, 1,   MOMP↓, 1,   p27↑, 1,   p‑p38↓, 1,   Paraptosis↑, 3,   survivin↓, 3,   TumCD↑, 1,  

Kinase & Signal Transduction

Sp1/3/4↓, 2,  

Transcription & Epigenetics

other↓, 1,   other↑, 2,   other↝, 1,   sonoS↑, 1,   tumCV↓, 7,  

Protein Folding & ER Stress

CHOP↑, 2,   p‑eIF2α↑, 1,   ER Stress↑, 7,   ER Stress↝, 1,   GRP78/BiP?, 1,   GRP78/BiP↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes

LC3B-II↑, 1,   LC3II↑, 1,   SESN2↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair

DNAdam↑, 5,   P53↑, 9,   cl‑PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence

CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   CycD3↓, 1,   P21↑, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State

ALDH↓, 1,   CD24↓, 1,   CD44↓, 1,   CSCs↓, 2,   ERK↓, 1,   FOXM1↓, 1,   IGF-1R↓, 3,   miR-125b↓, 1,   mTOR↓, 3,   p‑P70S6K↓, 1,   PI3K↓, 5,   p‑PI3K↓, 2,   STAT3↓, 1,   TOP1↓, 1,   TumCG?, 1,   TumCG↓, 5,   TumCG↑, 1,  

Migration

Alix/AIP‑1↓, 1,   FAK↓, 1,   Furin↓, 3,   MMP2↓, 1,   MMP9↓, 1,   TIMP2↑, 1,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 6,   TumCP↑, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   EGFR↓, 1,   EGR4↓, 1,   EPR↑, 2,   VEGF↑, 1,  

Barriers & Transport

CellMemb↑, 2,  

Immune & Inflammatory Signaling

COX2↑, 1,   IKKα↓, 1,   IL1β↑, 1,   NF-kB↓, 3,   NF-kB↑, 2,   PD-L1↑, 1,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors

ERα/ESR1↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 8,   ChemoSen∅, 1,   Dose↓, 1,   Dose↝, 1,   eff↓, 5,   eff↑, 12,   Half-Life↓, 1,   RadioS↑, 4,   selectivity↑, 11,  

Clinical Biomarkers

EGFR↓, 1,   ERα/ESR1↓, 1,   Ferritin↓, 1,   FOXM1↓, 1,   LDH↓, 1,   PD-L1↑, 1,  

Functional Outcomes

AntiCan↑, 1,   AntiTum↑, 2,   chemoP↑, 3,   neuroP↑, 1,   OS↑, 1,   RenoP↑, 1,   toxicity↝, 1,   TumVol↓, 2,  
Total Targets: 180

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 4,   GSH↑, 1,   lipid-P↓, 1,   ROS↓, 1,   ROS∅, 5,  

Metal & Cofactor Biology

IronCh↑, 1,  

Core Metabolism/Glycolysis

GlucoseCon↑, 1,  

Transcription & Epigenetics

Ach↑, 1,   other↓, 1,   other↝, 1,  

Immune & Inflammatory Signaling

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 2,  

Synaptic & Neurotransmission

ChAT↑, 1,  

Drug Metabolism & Resistance

BioAv↑, 2,   BioAv↝, 1,   Half-Life↓, 1,  

Clinical Biomarkers

IL6↓, 1,  

Functional Outcomes

memory↑, 1,   neuroP↑, 1,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 22

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
22 Silver-NanoParticles
9 Curcumin
9 Magnetic Fields
7 doxorubicin
7 Ashwagandha(Withaferin A)
7 Piperlongumine
6 Resveratrol
5 Radiotherapy/Radiation
5 Alpha-Lipoic-Acid
5 Propolis -bee glue
5 salinomycin
5 Selenite (Sodium)
5 Thymoquinone
4 Betulinic acid
4 Quercetin
3 Berberine
3 Sulforaphane (mainly Broccoli)
3 Copper and Cu NanoParticles
3 EGCG (Epigallocatechin Gallate)
3 Vitamin C (Ascorbic Acid)
2 SonoDynamic Therapy UltraSound
2 Allicin (mainly Garlic)
2 Apigenin (mainly Parsley)
2 Artemisinin
2 Ascorbyl Palmitate
2 Gold NanoParticles
2 Docetaxel
2 Biochanin A
2 Boswellia (frankincense)
2 Carnosic acid
2 chitosan
2 Dichloroacetate
2 Gambogic Acid
2 Graviola
2 Lycopene
2 Phenethyl isothiocyanate
2 Parthenolide
2 Silymarin (Milk Thistle) silibinin
2 Shikonin
2 Vitamin K2
1 Auranofin
1 Anzaroot, Astragalus fasciculifolius Bioss
1 Andrographis
1 Cisplatin
1 immunotherapy
1 Gemcitabine (Gemzar)
1 Atorvastatin
1 Baicalein
1 5-fluorouracil
1 Lapatinib
1 brusatol
1 Brucea javanica
1 Carvacrol
1 Thymol-Thymus vulgaris
1 Coenzyme Q10
1 Hydroxycinnamic-acid
1 Black phosphorus
1 methylseleninic acid
1 Metformin
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 Ellagic acid
1 Electrical Pulses
1 Fisetin
1 Galloflavin
1 Garcinol
1 γ-linolenic acid (Borage Oil)
1 Juglone
1 Luteolin
1 Melatonin
1 Magnesium
1 Myrrh
1 Pachymic acid
1 Sulfasalazine
1 Selenium NanoParticles
1 Iron
1 Ursolic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:275  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page